CpG ImmunoPharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Pharmaceuticals; DNA Immunotherapeutics. A particular DNA sequence, cytosine followed by guanine (CpG) common in bacterial and viral DNA and rare in human DNA may produce therapeutic immune responses in humans. CpG ImmunoPharmaceuticals is developing a vaccine for hepatitis B, and a cancer adjuvant. CpG's DNA therapy may be applicable to a wide range of immunological disorders, from asthma to lupus.